Brown Capital Management LLC Reduces Stock Position in TransMedics Group, Inc. $TMDX

Brown Capital Management LLC trimmed its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 30.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 313,855 shares of the company’s stock after selling 137,516 shares during the period. TransMedics Group comprises 1.5% of Brown Capital Management LLC’s portfolio, making the stock its 27th largest position. Brown Capital Management LLC owned 0.92% of TransMedics Group worth $35,215,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Whittier Trust Co. of Nevada Inc. raised its position in TransMedics Group by 981.0% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock valued at $26,000 after purchasing an additional 206 shares during the last quarter. Salomon & Ludwin LLC purchased a new position in shares of TransMedics Group during the third quarter valued at approximately $28,000. Pilgrim Partners Asia Pte Ltd bought a new position in shares of TransMedics Group during the third quarter valued at approximately $40,000. First Horizon Corp purchased a new stake in TransMedics Group in the third quarter worth $43,000. Finally, Elevation Point Wealth Partners LLC bought a new stake in TransMedics Group in the second quarter valued at $48,000. 99.67% of the stock is owned by institutional investors.

Insider Activity at TransMedics Group

In other TransMedics Group news, Director David Weill sold 5,000 shares of the stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total transaction of $693,200.00. Following the sale, the director directly owned 12,134 shares in the company, valued at approximately $1,682,257.76. This trade represents a 29.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Anil P. Ranganath sold 3,000 shares of the business’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total value of $435,660.00. Following the completion of the transaction, the insider owned 13,955 shares of the company’s stock, valued at $2,026,545.10. This represents a 17.69% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 8,920 shares of company stock valued at $1,257,310. 7.00% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have commented on TMDX shares. Weiss Ratings restated a “hold (c)” rating on shares of TransMedics Group in a report on Wednesday, October 8th. Jefferies Financial Group assumed coverage on shares of TransMedics Group in a research note on Monday, October 13th. They issued a “buy” rating and a $145.00 price target for the company. Morgan Stanley raised their price objective on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Needham & Company LLC increased their target price on TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Finally, Canaccord Genuity Group lifted their price target on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Six analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $144.25.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $133.99 on Tuesday. TransMedics Group, Inc. has a 1-year low of $62.07 and a 1-year high of $156.00. The business has a fifty day moving average price of $134.17 and a 200-day moving average price of $123.88. The company has a market capitalization of $4.58 billion, a PE ratio of 54.25 and a beta of 2.03. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.